Sign in
Not yet taking people in United StatesNo phase

Testing a wrist-worn glucose monitor that does not puncture the skin

Tests a wrist-worn glucose monitor in adults with diabetes or prediabetes.

Key facts

Who runs it
KOS Inc.
Where
San Mateo, United StatesSee the site
Trial code
Registry title
Argus 2.0 Adoption Study
Status
Not yet recruiting
People taking part
100 people, planned
Started
19 Apr 2026
Expected to end
19 Aug 2027
Type of study
Interventional
Treatments tested
  • KOS Argus Continuous Glucose Monitoring System
Record updated
20 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes, type 2 diabetes, or prediabetes to test a wrist-worn glucose monitor that does not puncture the skin.

Age
18 years and older (the registry lists a maximum age of 75 years).
Sex
All sexes can join.
Disease stage
A doctor's diagnosis of type 1 or type 2 diabetes and/or prediabetes, of any duration.
Earlier treatment
No earlier treatment is required. People who took part in another device or drug trial within 30 days cannot join.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Anemia (hematocrit below 36.0% for males or 33.0% for females)
  • Heart or blood vessel disease, or an active implanted device such as a pacemaker
  • Any cancer except basal cell or squamous cell skin cancer
  • End stage kidney disease treated with dialysis, or a history of hepatitis B, hepatitis C, or HIV

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Male or female, aged 18 years and older
  • Clinical diagnosis of type 1 or type 2 diabetes and/or prediabetes for any duration
  • Sufficient venous access for one IV line
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Willing to wear the required number of CGM systems for the total duration of the study (up to 15 days of total wear), including up to two Argus devices and at least one provided, commercially available, CGM device
  • Willing and able to use a compatible personal iOS or Android smartphone with - Bluetooth capability to install and use the study application, and to pair and maintain continuous Bluetooth communication between the smartphone and the investigational device for the required wear period
  • Has reliable access to their personal smartphone for the duration of participation and agrees to keep Bluetooth enabled and the study app running as instructed

Who cannot take part

  • Known or suspected hypersensitivity to any of the components of the investigational device
  • Presence of signs of acute illness or immunodeficiency Presence of any serious systemic infectious disease during four weeks prior to the intervention
  • Known allergy to medical grade adhesives
  • Presence of any injury, infection, atypical skin condition (such as hyperkeratosis or hyperpigmentation) or tattoo on the wrists
  • Presence or history of a cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, or clinically significant conduction disorders
  • Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer
  • History of significant alcohol or drug abuse, or current alcohol consumption exceeding approximately two standard drinks per day for males or one standard drink per day for females
  • Inability or unwillingness to refrain from smoking for the duration of visits History of diagnosis for hepatitis B, hepatitis C, HIV 1, or HIV 2
  • Clinically relevant comorbidity capable of constituting a risk for the participant or interfering with interpretation of data as judged by the investigator, including but not limited to end stage renal disease currently managed by dialysis or anticipating initiating dialysis during the study wear period, current usage of hydroxyurea medications, or significant usage of acetaminophen over 1 g every 6 hours
  • Presence of clinically significant abnormal screening laboratory tests or standard 12 lead electrocardiogram after 5 minutes resting in supine position at screening
  • Current or past affiliation with the investigational site, sponsor, or study personnel, including being an employee, contractor, or immediate family member of any individual directly involved in the trial, or current employment with, contractor relationship with, or significant financial interest in companies involved in glucose monitoring or diabetes related products that could create a conflict of interest or bias study results
  • Participation in any clinical trial investigation of a medical device or any medicinal product in clinical development within 30 days
  • Required or scheduled to have a Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, or diathermy during the study wear period
  • Blood donation or blood loss of more than 500 mL within the last 3 months
  • Presence of anemia as demonstrated by hematocrit measurements below 36.0% for males or 33.0% for females
  • Presence of an active implantable medical device such as a pacemaker
  • Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation Pregnancy or current breastfeeding
  • Consideration of unsuitability for inclusion by investigator Inability or unwillingness to use a compatible personal smartphone to install and operate the study app and maintain Bluetooth connectivity as required

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Mills-Peninsula Medical Center - San Mateo CampusSan Mateo, United StatesContact: Irina NaybergNot yet recruiting

About the trial

What the trial wants to find out

This study evaluates the usability of the KOS Argus Continuous Glucose Monitoring (CGM) System, a noninvasive, wrist-worn device that estimates blood glucose levels using light-based sensors and artificial intelligence algorithms. The Argus device does not puncture the skin or require sensor insertions.

Read full original descriptionShow less

The study will enroll up to 100 adults with type 1 diabetes, type 2 diabetes, or prediabetes at a single site. Participants will complete a screening visit, followed by a Day 1 in-clinic baseline visit that includes serial venous blood draws approximately every 10 minutes over 6 hours to collect paired reference blood glucose measurements alongside Argus device readings. After the baseline visit, participants will wear the Argus device and a commercially available Dexcom Stelo CGM continuously for 15 days during normal daily activities.

The primary objective is to collect paired glucose data to support device development and algorithm training. Participants will not receive glucose readings from the Argus device and will continue their usual diabetes management throughout the study. Secondary objectives include assessing device safety, tolerability, adherence, and operational lifespan over the 15-day wear period.

The group in the trial

  • Argus CGM FeasibilityTreatment being tested

    All participants will wear the investigational KOS Argus CGM device and a commercially available Dexcom Stelo CGM for 15 days. On Day 1, participants will complete an in-clinic baseline visit with serial venous blood sampling approximately every 10 minutes over 6 hours to collect paired reference glucose measurements alongside Argus readings. From Day 1 through Day 15, participants will wear both devices continuously during normal daily activities. Participants will provide a fingerstick blood glucose reference measurement every 5 days using a Contour Next One meter and log meals, medications, and activities in the Argus mobile application.

    Treatment: KOS Argus Continuous Glucose Monitoring System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Argus 2.0 Adoption Study
Plain-language title
Testing a wrist-worn glucose monitor that does not puncture the skinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07425236, who can take part
Record updated
20 February 2026